A citation-based method for searching scientific literature


List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
Rathi N Pillai, Madhusmita Behera, Lynne D Berry, Mike R Rossi, Mark G Kris, Bruce E Johnson, Paul A Bunn, Suresh S Ramalingam, Fadlo R Khuri. Cancer 2017
69
100

The interplay of immunotherapy and chemotherapy: harnessing potential synergies.
Leisha A Emens, Gary Middleton. Cancer Immunol Res 2015
336
100

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
J Mazières, F Barlesi, T Filleron, B Besse, I Monnet, M Beau-Faller, S Peters, E Dansin, M Früh, M Pless,[...]. Ann Oncol 2016
167
100

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Junji Tsurutani, Hiroji Iwata, Ian Krop, Pasi A Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles Redfern, Kenji Tamura, Trisha M Wise-Draper,[...]. Cancer Discov 2020
61
100

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
100

Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms.
Mu-Yang Huang, Xiao-Ming Jiang, Bing-Lin Wang, Yang Sun, Jin-Jian Lu. Pharmacol Ther 2021
10
100

Immunotherapy in non-small cell lung cancer harbouring driver mutations.
Alfredo Addeo, Antonio Passaro, Umberto Malapelle, Giuseppe Luigi Banna, Vivek Subbiah, Alex Friedlaender. Cancer Treat Rev 2021
8
100

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
100

Lung cancer: intragenic ERBB2 kinase mutations in tumours.
Philip Stephens, Chris Hunter, Graham Bignell, Sarah Edkins, Helen Davies, Jon Teague, Claire Stevens, Sarah O'Meara, Raffaella Smith, Adrian Parker,[...]. Nature 2004
577
100

Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations.
Felix C Saalfeld, Carina Wenzel, Petros Christopoulos, Sabine Merkelbach-Bruse, Timm M Reissig, Silke Laßmann, Sebastian Thiel, Jan A Stratmann, Ralf Marienfeld, Johannes Berger,[...]. J Thorac Oncol 2021
1
100

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
100

Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain.
Makoto Sonobe, Toshiaki Manabe, Hiromi Wada, Fumihiro Tanaka. J Mol Diagn 2006
31
100

Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
Sally C M Lau, Aline Fusco Fares, Lisa W Le, Kate M Mackay, Spencer Soberano, Sze Wah Chan, Elliot Smith, Malcolm Ryan, Ming Sound Tsao, Penelope A Bradbury,[...]. Clin Lung Cancer 2021
10
100

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
Florian Guisier, Catherine Dubos-Arvis, Florent Viñas, Helene Doubre, Charles Ricordel, Stanislas Ropert, Henri Janicot, Marie Bernardi, Pierre Fournel, Régine Lamy,[...]. J Thorac Oncol 2020
69
100

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Caicun Zhou, Yi-Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren,[...]. Lancet Oncol 2011
100

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
278
100

Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study.
Caicun Zhou, Xingya Li, Qiming Wang, Guanghui Gao, Yiping Zhang, Jianhua Chen, Yongqian Shu, Yanping Hu, Yun Fan, Jian Fang,[...]. J Clin Oncol 2020
31
100

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.
Hisayuki Shigematsu, Takao Takahashi, Masaharu Nomura, Kuntal Majmudar, Makoto Suzuki, Huei Lee, Ignacio I Wistuba, Kwun M Fong, Shinichi Toyooka, Nobuyoshi Shimizu,[...]. Cancer Res 2005
494
100



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.